Skip to main content
. 2016 Aug 15;5(8):e253. doi: 10.1038/oncsis.2016.47

Figure 3.

Figure 3

Immunohistochemical analyses of RCAN2 and other markers at invasive front of cancer. Representative IHC images of KRAS wild-type (ae) and KRAS-mutated (fj) human CRC tissue samples, stained with anti-RCAN2 (a, f), anti-Ki-67 (b, g), anti-CDX2 (c, h), anti-VEGF-A (d, i), and anti-p53 (e, j) antibodies.